Zacks Research Weighs in on ResMed’s Q1 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Stock analysts at Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for shares of ResMed in a note issued to investors on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.25 per share for the quarter, up from their prior forecast of $2.13. The consensus estimate for ResMed’s current full-year earnings is $9.28 per share. Zacks Research also issued estimates for ResMed’s Q1 2027 earnings at $2.44 EPS.

Several other equities research analysts have also issued reports on the company. Bank of America raised their price objective on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, September 26th. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Friday, October 25th. Royal Bank of Canada lifted their price objective on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research note on Friday, October 25th. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, KeyCorp lifted their price target on shares of ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ResMed presently has a consensus rating of “Moderate Buy” and a consensus target price of $225.70.

ResMed Stock Up 1.4 %

Shares of NYSE:RMD opened at $234.74 on Friday. The company has a 50-day moving average price of $242.83 and a 200 day moving average price of $223.55. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed has a 12 month low of $147.39 and a 12 month high of $260.49. The company has a market cap of $34.46 billion, a price-to-earnings ratio of 31.09, a PEG ratio of 1.71 and a beta of 0.69.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same period last year, the company posted $1.64 EPS. The business’s revenue was up 11.1% on a year-over-year basis.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.90%. ResMed’s dividend payout ratio is currently 28.08%.

Insiders Place Their Bets

In other news, General Counsel Michael J. Rider sold 882 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total transaction of $203,742.00. Following the transaction, the general counsel now owns 10,512 shares in the company, valued at approximately $2,428,272. This trade represents a 7.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kaushik Ghoshal sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the completion of the sale, the insider now directly owns 21,788 shares of the company’s stock, valued at approximately $5,502,777.28. This trade represents a 18.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,056 shares of company stock worth $15,086,020 in the last three months. Corporate insiders own 0.71% of the company’s stock.

Hedge Funds Weigh In On ResMed

Several institutional investors have recently bought and sold shares of RMD. Geode Capital Management LLC raised its stake in shares of ResMed by 10.9% in the third quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider’s stock worth $939,114,000 after purchasing an additional 380,383 shares during the last quarter. Brophy Wealth Management LLC acquired a new position in ResMed during the third quarter valued at $352,000. Vestcor Inc boosted its holdings in ResMed by 15.3% in the third quarter. Vestcor Inc now owns 3,182 shares of the medical equipment provider’s stock valued at $777,000 after purchasing an additional 422 shares during the last quarter. M&T Bank Corp boosted its holdings in ResMed by 4.5% in the third quarter. M&T Bank Corp now owns 10,737 shares of the medical equipment provider’s stock valued at $2,622,000 after purchasing an additional 462 shares during the last quarter. Finally, Executive Wealth Management LLC acquired a new stake in ResMed during the third quarter worth about $3,347,000. 54.98% of the stock is owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.